Among the recent advances in the treatment of extensive-stage SCLC is the bispecific T-cell engager, tarlatamab, which targets DLL3 and CD3 to facilitate T-cell lysis of tumor cells.6 Here, DLL3 is linked to small cell lung carcinoma.